DEC0010549MA - - Google Patents
Info
- Publication number
- DEC0010549MA DEC0010549MA DEC0010549MA DE C0010549M A DEC0010549M A DE C0010549MA DE C0010549M A DEC0010549M A DE C0010549MA
- Authority
- DE
- Germany
- Prior art keywords
- ester
- acid
- group
- esters
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000001243 acetic acids Chemical class 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- -1 dimethylaminoethyl Chemical group 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
BUNDESREPUBLIK DEUTSCHLANDFEDERAL REPUBLIC OF GERMANY
Tag der Anmeldung: 11. Januar 1955 Bekanntgiemaciht am 30. August 1956Date of registration: January 11, 1955 Published on August 30, 1956
DEUTSCHES PATENTAMTGERMAN PATENT OFFICE
PATENTANMELDUNGPATENT APPLICATION
KLASSE 12 q GRUPPE 3201 INTERNAT. KLASSE C07c CLASS 12 q GROUP 3201 INTERNAT. CLASS C07c
C 10549 IYbIUqC 10549 IYbIUq
Dr. Hellmuth Pflugk, Berlin-WannseeDr. Hellmuth Pflugk, Berlin-Wannsee
ist als Erfinder genannt wordenhas been named as the inventor
Chemische Fabrik Tempelhof Preuß & Temmler, Berlin-TempelhofChemical factory Tempelhof Preuss & Temmler, Berlin-Tempelhof
Verfahren zur Herstellung von neuen pharmakologisch wirksamen basischen Estern und ihren SalzenProcess for the preparation of new pharmacologically active basic esters and their salts
Die Herstellung basischer Ester der mono-, dioder trisubstituierten Essigsäuren von der allgemeinen FormelThe preparation of basic esters of mono-, di- or trisubstituted acetic acids from the general formula
-,C-COO -CH2- CH2 -N (R -, C- COO -CH 2 - CH 2 -N (R
■4.12■ 4.12
ist sowohl aus der Literatur als auch aus zahlreichen Patenten hinreichend bekannt. Als Substituenten R1, R2, R3 wurden Alkyl-, Aryl-, alicyclische, basische u. a. Gruppen eingeführt. Es sind ferner Dialkylaminoalkylester substituierter Essigsäuren, bekannt, in denen ein H der CH3-Gruppe durch eine Alkenylgruppe substituiert ist, z, B. durch eine 2-Methyl-propeinyl-Gruppe, eine Cyolo^ hexenylgruppe, eine Allylgruppe oder eine Meth,-allylgruppe. Allen diesen Estern ist eine mehr oder weniger starke, spasmolytische Wirkung zu eigen, derzufoJge mehrere vo-n ihnen Verwendung in der Therapie gefunden haben,is well known both from the literature and from numerous patents. As substituents R 1 , R 2 , R 3 , alkyl, aryl, alicyclic, basic, etc. groups were introduced. There are also dialkylaminoalkyl esters of substituted acetic acids known in which one H of the CH 3 group is substituted by an alkenyl group, for example by a 2-methylpropeinyl group, a Cyolo ^ hexenyl group, an allyl group or a meth, allyl group. All of these esters have a more or less strong spasmolytic effect, which is why several of them have found use in therapy,
Es wurde nun gefunden, daß die Herstellung der bisher unbekannten Dialkylaminoiäthylester der Phenyldiallylessigsäurei zu basischen Estern führt, die außer der spasmolytisehen auch blutdrucksenkende Wirkung zeigen.It has now been found that the preparation of the previously unknown Dialkylaminoiäthylester Phenyldiallylacetic acid leads to basic esters which, in addition to being spasmolytic, are also antihypertensive Show effects.
609 616/502609 616/502
C 10549 IVb/12qC 10549 IVb / 12q
Überraschenderweise wurde weiterhin festgestellt, daß speziell durch das Phenyldiallylaeetyldiäthylaminoäthylester-hydrochlorid die Schlafwirkung von Barbiturate« (wie N-Methyl-cyclo>hexenyl-miethyibarbitursäure, Natriumsalz der /J-Broimallyl-sek.-butylbarbitursäure, ß-Broniallylisopropyl -N- methylbarbitursäure, β - Isopröpylbromallyl-barbitursäure usw.) beträchtlich verlängert wird. So wurde in der pharmakologischenSurprisingly, it was furthermore found that especially the effect of barbiturates sleep "(such as N-methyl-cyclo> hexenyl-miethyibarbitursäure, sodium salt hydrochloride Phenyldiallylaeetyldiäthylaminoäthylester-through which the /J-Broimallyl-sek.-butylbarbitursäure, ß-Broniallylisopropyl -N- methylbarbituric acid, β - Isopropylbromoallyl-barbituric acid, etc.) is considerably lengthened. So it was in the pharmacological
ίο Prüfung gefunden, daß durch eine einmalige orale Dosis von 50 mg Phmyldiallylacetyl-diäthyla.miiw>äthylester-hydroehilorid pro kg die Schlafwirkung von N - Methyl - cyclohexenyl - methylbarbitursäure um etwa das iofachie verlängert wird. Besonders bemerkenswert ist,, daß diese Wirkung1 eintritt, , gleichgültig ob die 50 mg als orale Gabe oder als peritoneal e Injektion gegeben werden, obwohl die Toxizität bei oraler Gabe nur etwa ein Zehntel der bei peritonealer Injektion beträgt. Diese Wirkungssteigerung beschränkt sich nicht nur auf Barbiturate, sondern ist unter anderem auch bei Penta,-mathylentetrazol und Succinylcholin (muiskelerschlaffende Wirkung) zu beobachten..ίο Test found that a single oral dose of 50 mg Phmyldiallylacetyl-diethyla.miiw> ethyl ester hydroehilorid per kg prolongs the sleep effect of N - methyl - cyclohexenyl - methylbarbituric acid by about iofachie. It is particularly noteworthy that this effect ,, 1 has occurred, regardless of whether the 50 mg as oral administration or peritoneal injection, e are given, although the toxicity only about one-tenth of the case of oral administration in peritoneal injection. This increase in effectiveness is not limited to barbiturates, but can also be observed, among other things, with penta, -mathylenetetrazole and succinylcholine (muscular sleeping effect).
Die Herstellung der neuen Verbindungen erfolgt durch die bekannten Methoden der Esterbildung und wird im- folgenden· beschrieben.The new compounds are produced using the known methods of ester formation and is described below.
ν Beispiel ιν example ι
204 g. Phenyldiallylaoetylchlorid (Kp.0i2 99 bis ΐοό°) und 102 g Diätliylaminoäthianol werden in einem Rundkolben zusammengegeben und im Ölbad auf 1500 C erhitzt. Die Reaktion ist beendet, wenn der Kolbeninhalt eine klare, blanke Flüssigkeit ist. Nunmehr wird der Kolbeninhalt in eine Schale gegossen, in der der Ester zu einer harten spröden Masse erstarrt. Nach dem Zerkleinern wird der rohe Ester aus Aceton umkristallisiert.204 g. Phenyldiallylaoetylchlorid (Kp. 99 to 0I2 ΐοό °) and 102 g Diätliylaminoäthianol are combined in a round bottom flask and heated in an oil bath at 150 0 C. The reaction has ended when the contents of the flask are a clear, shiny liquid. The contents of the flask are then poured into a bowl in which the ester solidifies to a hard, brittle mass. After grinding, the crude ester is recrystallized from acetone.
Das reine Phenyldiallylacetyl-diäthylaminoäithylester-hydrochlorid schmilzt bei 139 bis 140°.The pure phenyldiallylacetyl diethylaminoethyl ester hydrochloride melts at 139 to 140 °.
Die Herstellung der Phenyldiallylessigsäurö bzw. ihres Chlorides erfolgt durch Einwirkung von Na N H2 auf ein Gemisch von Phenylacetonitril und Allylbromid zu Phenyldiallylacetonitril, Verseifung des Nitrils zur Phenyldiiallylessigsäure und ChIo^ rierung der Säure mittels SOCl2 zum Phenyldiallylacetylchlorid. Λ'^ Phenyldiallylacetonitrile or its chloride is produced by the action of Na NH 2 on a mixture of phenylacetonitrile and allyl bromide to form phenyldiallylacetonitrile, saponification of the nitrile to form phenyldiiallylacetic acid and chlorination of the acid by means of SOCl 2 to form phenyldiallylacetonitrile. Λ '^
50 g Phenyldialiylacetylchlorid und 40 g Dimethylarninoäthanol, in je 100 ecm Benzol gelöst, werden in einem Rundkolben zusammengegeben und 4 Stunden auf dem Dampfbad zum Sieden erhitzt. Nach dem Erkalten wird der Kolbeninhalt mit Wasser ausgeschüttelt, die Benzollösung getrocknet, das Benzol abdestilliert und der Rückstand im Hochvakuum destilliert. Der Phenyldiallylacetyl-dimethylaminoäthyleister siedet bei 0,4 bis 0,5 mm und 130 bis 1330.50 g of phenyldialiylacetyl chloride and 40 g of dimethylarninoethanol, each dissolved in 100 ecm of benzene, are put together in a round bottom flask and heated to the boil for 4 hours on the steam bath. After cooling, the contents of the flask are shaken out with water, the benzene solution is dried, the benzene is distilled off and the residue is distilled in a high vacuum. The Phenyldiallylacetyl-dimethylaminoäthyleister boils at 0.4 to 0.5 mm and 130 to 133 0 .
Der Ester wird in trocknem Äther gelöst, und unter Rühren wird trockenes HCl-Gas darübergeleitet. Das ausgefallene Hydrochlorid des Esters wird abgesaugt, getrocknet und aus Essigester umkristaUisiert. Das reine Phenyldiallylacetyl-dimethylaminoäthylester-hydrochlorid schmilzt bei, 118 bis 1190.The ester is dissolved in dry ether and dry HCl gas is passed over it with stirring. The precipitated hydrochloride of the ester is filtered off with suction, dried and recrystallized from ethyl acetate. The pure phenyldiallylacetyl dimethylaminoethyl ester hydrochloride melts at from 118 to 119 0 .
Claims (1)
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT363096B (en) | METHOD FOR PRODUCING NEW PHTHALAZINE DERIVATIVES AND THEIR SALTS | |
| DD202715A5 (en) | PROCESS FOR THE PRODUCTION OF SUBSTITUTED DERIVATIVES OF PYRIDAZINE | |
| DE1948144C3 (en) | 1 - (I -Keto-tetrahydronaphthyl-5-oxy) ^ -hydroxy-S-alkylaminopropanes, process for their preparation and pharmaceutical composition based on them | |
| DE1294375B (en) | Process for the preparation of aminopropylidene-9, 10-dihydroanthracenes with antidepressant activity | |
| DE2059985C3 (en) | Right-handed, basic substituted phenylacetonitriles, processes for their preparation and pharmaceuticals containing these compounds | |
| DE2449205C2 (en) | Substituted furyl compounds, processes for their preparation and pharmaceuticals containing these compounds | |
| AT391866B (en) | METHOD FOR PRODUCING NEW S-TRIAZOLO (1,5-A) PYRIMIDINE | |
| DE3107743A1 (en) | NEW CLASS OF ACYL DERIVATIVES OF CARNITINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR THERAPEUTIC USE | |
| DE1670497B2 (en) | ISOCHINOLINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
| DE2000030C3 (en) | 3-alkoxy- and 3-phenoxy-2- (diphenylhydroxy) methyl-propylamines and medicaments containing them | |
| DEC0010549MA (en) | ||
| DE2456098C3 (en) | Xanthene and thioxanthene derivatives, processes for their preparation and pharmaceuticals containing these compounds | |
| DE959015C (en) | Process for the preparation of new pharmacologically active basic esters and their salts | |
| DE1008737B (en) | Process for the preparation of phenthiazine derivatives | |
| DD150060A5 (en) | PROCESS FOR THE PREPARATION OF NEW PHENTHIAZINE DERIVATIVES | |
| DE69001461T2 (en) | STEREOISOMERE. | |
| DE1670143C3 (en) | ||
| DE3620215A1 (en) | BENZAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM | |
| DE905244C (en) | Process for the production of new thioether and their quaternary and acid salts | |
| DE1445969C (en) | Process for the preparation of basic 3,4,5 trimethoxybenzoic acid esters | |
| AT394045B (en) | NEW SULFAMOYL THIOPHENES, METHOD FOR THEIR PRODUCTION AND THEIR USE | |
| CH511816A (en) | Substd phenacrylquanidines | |
| DE1156814B (en) | Process for the preparation of ª-morpholino-fatty acid anilides | |
| DE1258416B (en) | Process for the preparation of L-alpha-methyl-beta- (3, 4-dihydroxyphenyl) -alanine | |
| DE1181231B (en) | Process for the preparation of d.1-, d- and 1-2-phenyl-3-methyl-butylamine- (3) and their salts |